K134 is a potent anti-thrombotic agent used for the prevention and treatment of thrombotic disorders, including ischemic stroke; it significantly prolongs middle cerebral artery occlusion time, reduces cerebral infarct size in stroke models, and inhibits platelet aggregation induced by collagen and ADP in both rats and mice in a dose-dependent manner; additionally, it demonstrates a low bleeding risk at effective anti-thrombotic doses.